INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6201, 11875, 'Methoxsalen', 'Photosensitivity Disorders', 'The use of methoxsalen with ultraviolet radiation is contraindicated in patients with a history of photosensitive disease states.  Methoxsalen is a potent photosensitizer that can induce severe burns and marked hyperpigmentation and aging of skin in susceptible patients or when used improperly.  Diseases associated with photosensitivity include lupus erythematosus, porphyria cutanea tarda, erythropoietic protoporphyria, variegate porphyria, xeroderma pigmentosum, and albinism.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6202, 23373, 'Methoxsalen', 'Photosensitivity Disorders', 'The use of methoxsalen with ultraviolet radiation is contraindicated in patients with a history of photosensitive disease states.  Methoxsalen is a potent photosensitizer that can induce severe burns and marked hyperpigmentation and aging of skin in susceptible patients or when used improperly.  Diseases associated with photosensitivity include lupus erythematosus, porphyria cutanea tarda, erythropoietic protoporphyria, variegate porphyria, xeroderma pigmentosum, and albinism.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6203, 28696, 'Methoxsalen', 'Photosensitivity Disorders', 'The use of methoxsalen with ultraviolet radiation is contraindicated in patients with a history of photosensitive disease states.  Methoxsalen is a potent photosensitizer that can induce severe burns and marked hyperpigmentation and aging of skin in susceptible patients or when used improperly.  Diseases associated with photosensitivity include lupus erythematosus, porphyria cutanea tarda, erythropoietic protoporphyria, variegate porphyria, xeroderma pigmentosum, and albinism.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6204, 8642, 'Methoxsalen', 'Skin Neoplasms', 'The use of methoxsalen (a psoralen) with ultraviolet radiation (UVA) is contraindicated in patients with melanoma, invasive squamous cell carcinomas, or a history of melanoma.  PUVA (psoralen and UVA photochemotherapy) may be associated with increased risks of squamous cell carcinoma, basal cell carcinoma and melanoma.  Methoxsalen markedly enhances skin reactivity to UVA, and exposure to sunlight and/or UVA can cause premature aging of the skin and skin cancer.  If necessary, patients with a current or past history of multiple basal cell carcinomas or other nonmelanoma skin cancers may be treated with PUVA but should be carefully monitored.  The usual restrictions concerning sun exposure before and after treatment as well as prescribed dosage must be followed closely.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6205, 11875, 'Methoxsalen', 'Skin Neoplasms', 'The use of methoxsalen (a psoralen) with ultraviolet radiation (UVA) is contraindicated in patients with melanoma, invasive squamous cell carcinomas, or a history of melanoma.  PUVA (psoralen and UVA photochemotherapy) may be associated with increased risks of squamous cell carcinoma, basal cell carcinoma and melanoma.  Methoxsalen markedly enhances skin reactivity to UVA, and exposure to sunlight and/or UVA can cause premature aging of the skin and skin cancer.  If necessary, patients with a current or past history of multiple basal cell carcinomas or other nonmelanoma skin cancers may be treated with PUVA but should be carefully monitored.  The usual restrictions concerning sun exposure before and after treatment as well as prescribed dosage must be followed closely.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6206, 23373, 'Methoxsalen', 'Skin Neoplasms', 'The use of methoxsalen (a psoralen) with ultraviolet radiation (UVA) is contraindicated in patients with melanoma, invasive squamous cell carcinomas, or a history of melanoma.  PUVA (psoralen and UVA photochemotherapy) may be associated with increased risks of squamous cell carcinoma, basal cell carcinoma and melanoma.  Methoxsalen markedly enhances skin reactivity to UVA, and exposure to sunlight and/or UVA can cause premature aging of the skin and skin cancer.  If necessary, patients with a current or past history of multiple basal cell carcinomas or other nonmelanoma skin cancers may be treated with PUVA but should be carefully monitored.  The usual restrictions concerning sun exposure before and after treatment as well as prescribed dosage must be followed closely.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6207, 28696, 'Methoxsalen', 'Skin Neoplasms', 'The use of methoxsalen (a psoralen) with ultraviolet radiation (UVA) is contraindicated in patients with melanoma, invasive squamous cell carcinomas, or a history of melanoma.  PUVA (psoralen and UVA photochemotherapy) may be associated with increased risks of squamous cell carcinoma, basal cell carcinoma and melanoma.  Methoxsalen markedly enhances skin reactivity to UVA, and exposure to sunlight and/or UVA can cause premature aging of the skin and skin cancer.  If necessary, patients with a current or past history of multiple basal cell carcinomas or other nonmelanoma skin cancers may be treated with PUVA but should be carefully monitored.  The usual restrictions concerning sun exposure before and after treatment as well as prescribed dosage must be followed closely.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6208, 8642, 'Methoxsalen', 'Heart Diseases', 'Patients with cardiac disease may not be able to tolerate prolonged standing or exposure to heat stress required of treatment in a vertical UVA chamber.  Therapy with methoxsalen, if used in patients with cardiac disease,  may require special precautions.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6209, 11875, 'Methoxsalen', 'Heart Diseases', 'Patients with cardiac disease may not be able to tolerate prolonged standing or exposure to heat stress required of treatment in a vertical UVA chamber.  Therapy with methoxsalen, if used in patients with cardiac disease,  may require special precautions.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6210, 23373, 'Methoxsalen', 'Heart Diseases', 'Patients with cardiac disease may not be able to tolerate prolonged standing or exposure to heat stress required of treatment in a vertical UVA chamber.  Therapy with methoxsalen, if used in patients with cardiac disease,  may require special precautions.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6211, 28696, 'Methoxsalen', 'Heart Diseases', 'Patients with cardiac disease may not be able to tolerate prolonged standing or exposure to heat stress required of treatment in a vertical UVA chamber.  Therapy with methoxsalen, if used in patients with cardiac disease,  may require special precautions.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6212, 8642, 'Methoxsalen', 'Liver Diseases', 'Patients with hepatic insufficiency should be treated with caution since hepatic biotransformation is necessary for drug urinary excretion.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6213, 11875, 'Methoxsalen', 'Liver Diseases', 'Patients with hepatic insufficiency should be treated with caution since hepatic biotransformation is necessary for drug urinary excretion.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6214, 23373, 'Methoxsalen', 'Liver Diseases', 'Patients with hepatic insufficiency should be treated with caution since hepatic biotransformation is necessary for drug urinary excretion.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6215, 28696, 'Methoxsalen', 'Liver Diseases', 'Patients with hepatic insufficiency should be treated with caution since hepatic biotransformation is necessary for drug urinary excretion.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6216, 8642, 'Methoxsalen', 'Sunburn', 'Patients presenting with a sunburn should not be treated with methoxsalen (a psoralen) and ultraviolet radiation (UVA), since it may be difficult to evaluate the response of these patients to therapy.  The mild, transient erythema normally seen 24 to 48 hours after PUVA (psoralen and UVA photochemotherapy) indicates a therapeutic interaction occurring between the psoralen and UVA but may be masked by a sunburn.  Patients generally should avoid sunbathing for at least 24 hours prior to methoxsalen administration and UVA exposure.  The usual restrictions concerning sun exposure after treatment and the prescribed dosage should also be followed closely to avoid severe burns and other phototoxic reactions.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6217, 11875, 'Methoxsalen', 'Sunburn', 'Patients presenting with a sunburn should not be treated with methoxsalen (a psoralen) and ultraviolet radiation (UVA), since it may be difficult to evaluate the response of these patients to therapy.  The mild, transient erythema normally seen 24 to 48 hours after PUVA (psoralen and UVA photochemotherapy) indicates a therapeutic interaction occurring between the psoralen and UVA but may be masked by a sunburn.  Patients generally should avoid sunbathing for at least 24 hours prior to methoxsalen administration and UVA exposure.  The usual restrictions concerning sun exposure after treatment and the prescribed dosage should also be followed closely to avoid severe burns and other phototoxic reactions.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6218, 23373, 'Methoxsalen', 'Sunburn', 'Patients presenting with a sunburn should not be treated with methoxsalen (a psoralen) and ultraviolet radiation (UVA), since it may be difficult to evaluate the response of these patients to therapy.  The mild, transient erythema normally seen 24 to 48 hours after PUVA (psoralen and UVA photochemotherapy) indicates a therapeutic interaction occurring between the psoralen and UVA but may be masked by a sunburn.  Patients generally should avoid sunbathing for at least 24 hours prior to methoxsalen administration and UVA exposure.  The usual restrictions concerning sun exposure after treatment and the prescribed dosage should also be followed closely to avoid severe burns and other phototoxic reactions.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6219, 28696, 'Methoxsalen', 'Sunburn', 'Patients presenting with a sunburn should not be treated with methoxsalen (a psoralen) and ultraviolet radiation (UVA), since it may be difficult to evaluate the response of these patients to therapy.  The mild, transient erythema normally seen 24 to 48 hours after PUVA (psoralen and UVA photochemotherapy) indicates a therapeutic interaction occurring between the psoralen and UVA but may be masked by a sunburn.  Patients generally should avoid sunbathing for at least 24 hours prior to methoxsalen administration and UVA exposure.  The usual restrictions concerning sun exposure after treatment and the prescribed dosage should also be followed closely to avoid severe burns and other phototoxic reactions.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6220, 5019, 'Methotrexate', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6221, 8089, 'Methotrexate', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6222, 11930, 'Methotrexate', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6223, 14338, 'Methotrexate', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6224, 14594, 'Methotrexate', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6225, 18291, 'Methotrexate', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6226, 22641, 'Methotrexate', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6227, 22644, 'Methotrexate', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6228, 22645, 'Methotrexate', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6229, 22647, 'Methotrexate', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6230, 22648, 'Methotrexate', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6231, 22649, 'Methotrexate', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6232, 22650, 'Methotrexate', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6233, 22651, 'Methotrexate', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6234, 22652, 'Methotrexate', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6235, 22653, 'Methotrexate', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6236, 22654, 'Methotrexate', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6237, 22655, 'Methotrexate', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6238, 22657, 'Methotrexate', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6239, 22786, 'Methotrexate', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6240, 23055, 'Methotrexate', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6241, 23056, 'Methotrexate', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6242, 28776, 'Methotrexate', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6243, 28778, 'Methotrexate', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6244, 28779, 'Methotrexate', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6245, 32982, 'Methotrexate', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6246, 32983, 'Methotrexate', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6247, 33198, 'Methotrexate', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6248, 5019, 'Methotrexate', 'Liver Diseases', 'The use of methotrexate is contraindicated as treatment for psoriasis or rheumatoid arthritis in patients with alcoholism, alcoholic liver disease or other chronic liver diseases.  Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, usually after long-term therapy.  Fibrosis and cirrhosis may not be preceded by symptoms or abnormal liver function tests.  If methotrexate is used, patients should be instructed to immediately report any signs or symptoms suggestive of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Persistent liver function test abnormalities and/or depression of serum albumin may require evaluation, including a liver biopsy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6249, 8089, 'Methotrexate', 'Liver Diseases', 'The use of methotrexate is contraindicated as treatment for psoriasis or rheumatoid arthritis in patients with alcoholism, alcoholic liver disease or other chronic liver diseases.  Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, usually after long-term therapy.  Fibrosis and cirrhosis may not be preceded by symptoms or abnormal liver function tests.  If methotrexate is used, patients should be instructed to immediately report any signs or symptoms suggestive of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Persistent liver function test abnormalities and/or depression of serum albumin may require evaluation, including a liver biopsy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6250, 11930, 'Methotrexate', 'Liver Diseases', 'The use of methotrexate is contraindicated as treatment for psoriasis or rheumatoid arthritis in patients with alcoholism, alcoholic liver disease or other chronic liver diseases.  Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, usually after long-term therapy.  Fibrosis and cirrhosis may not be preceded by symptoms or abnormal liver function tests.  If methotrexate is used, patients should be instructed to immediately report any signs or symptoms suggestive of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Persistent liver function test abnormalities and/or depression of serum albumin may require evaluation, including a liver biopsy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6251, 14338, 'Methotrexate', 'Liver Diseases', 'The use of methotrexate is contraindicated as treatment for psoriasis or rheumatoid arthritis in patients with alcoholism, alcoholic liver disease or other chronic liver diseases.  Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, usually after long-term therapy.  Fibrosis and cirrhosis may not be preceded by symptoms or abnormal liver function tests.  If methotrexate is used, patients should be instructed to immediately report any signs or symptoms suggestive of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Persistent liver function test abnormalities and/or depression of serum albumin may require evaluation, including a liver biopsy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6252, 14594, 'Methotrexate', 'Liver Diseases', 'The use of methotrexate is contraindicated as treatment for psoriasis or rheumatoid arthritis in patients with alcoholism, alcoholic liver disease or other chronic liver diseases.  Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, usually after long-term therapy.  Fibrosis and cirrhosis may not be preceded by symptoms or abnormal liver function tests.  If methotrexate is used, patients should be instructed to immediately report any signs or symptoms suggestive of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Persistent liver function test abnormalities and/or depression of serum albumin may require evaluation, including a liver biopsy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6253, 18291, 'Methotrexate', 'Liver Diseases', 'The use of methotrexate is contraindicated as treatment for psoriasis or rheumatoid arthritis in patients with alcoholism, alcoholic liver disease or other chronic liver diseases.  Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, usually after long-term therapy.  Fibrosis and cirrhosis may not be preceded by symptoms or abnormal liver function tests.  If methotrexate is used, patients should be instructed to immediately report any signs or symptoms suggestive of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Persistent liver function test abnormalities and/or depression of serum albumin may require evaluation, including a liver biopsy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6254, 22641, 'Methotrexate', 'Liver Diseases', 'The use of methotrexate is contraindicated as treatment for psoriasis or rheumatoid arthritis in patients with alcoholism, alcoholic liver disease or other chronic liver diseases.  Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, usually after long-term therapy.  Fibrosis and cirrhosis may not be preceded by symptoms or abnormal liver function tests.  If methotrexate is used, patients should be instructed to immediately report any signs or symptoms suggestive of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Persistent liver function test abnormalities and/or depression of serum albumin may require evaluation, including a liver biopsy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6255, 22644, 'Methotrexate', 'Liver Diseases', 'The use of methotrexate is contraindicated as treatment for psoriasis or rheumatoid arthritis in patients with alcoholism, alcoholic liver disease or other chronic liver diseases.  Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, usually after long-term therapy.  Fibrosis and cirrhosis may not be preceded by symptoms or abnormal liver function tests.  If methotrexate is used, patients should be instructed to immediately report any signs or symptoms suggestive of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Persistent liver function test abnormalities and/or depression of serum albumin may require evaluation, including a liver biopsy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6256, 22645, 'Methotrexate', 'Liver Diseases', 'The use of methotrexate is contraindicated as treatment for psoriasis or rheumatoid arthritis in patients with alcoholism, alcoholic liver disease or other chronic liver diseases.  Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, usually after long-term therapy.  Fibrosis and cirrhosis may not be preceded by symptoms or abnormal liver function tests.  If methotrexate is used, patients should be instructed to immediately report any signs or symptoms suggestive of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Persistent liver function test abnormalities and/or depression of serum albumin may require evaluation, including a liver biopsy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6257, 22647, 'Methotrexate', 'Liver Diseases', 'The use of methotrexate is contraindicated as treatment for psoriasis or rheumatoid arthritis in patients with alcoholism, alcoholic liver disease or other chronic liver diseases.  Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, usually after long-term therapy.  Fibrosis and cirrhosis may not be preceded by symptoms or abnormal liver function tests.  If methotrexate is used, patients should be instructed to immediately report any signs or symptoms suggestive of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Persistent liver function test abnormalities and/or depression of serum albumin may require evaluation, including a liver biopsy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6258, 22648, 'Methotrexate', 'Liver Diseases', 'The use of methotrexate is contraindicated as treatment for psoriasis or rheumatoid arthritis in patients with alcoholism, alcoholic liver disease or other chronic liver diseases.  Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, usually after long-term therapy.  Fibrosis and cirrhosis may not be preceded by symptoms or abnormal liver function tests.  If methotrexate is used, patients should be instructed to immediately report any signs or symptoms suggestive of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Persistent liver function test abnormalities and/or depression of serum albumin may require evaluation, including a liver biopsy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6259, 22649, 'Methotrexate', 'Liver Diseases', 'The use of methotrexate is contraindicated as treatment for psoriasis or rheumatoid arthritis in patients with alcoholism, alcoholic liver disease or other chronic liver diseases.  Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, usually after long-term therapy.  Fibrosis and cirrhosis may not be preceded by symptoms or abnormal liver function tests.  If methotrexate is used, patients should be instructed to immediately report any signs or symptoms suggestive of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Persistent liver function test abnormalities and/or depression of serum albumin may require evaluation, including a liver biopsy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6260, 22650, 'Methotrexate', 'Liver Diseases', 'The use of methotrexate is contraindicated as treatment for psoriasis or rheumatoid arthritis in patients with alcoholism, alcoholic liver disease or other chronic liver diseases.  Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, usually after long-term therapy.  Fibrosis and cirrhosis may not be preceded by symptoms or abnormal liver function tests.  If methotrexate is used, patients should be instructed to immediately report any signs or symptoms suggestive of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Persistent liver function test abnormalities and/or depression of serum albumin may require evaluation, including a liver biopsy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6261, 22651, 'Methotrexate', 'Liver Diseases', 'The use of methotrexate is contraindicated as treatment for psoriasis or rheumatoid arthritis in patients with alcoholism, alcoholic liver disease or other chronic liver diseases.  Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, usually after long-term therapy.  Fibrosis and cirrhosis may not be preceded by symptoms or abnormal liver function tests.  If methotrexate is used, patients should be instructed to immediately report any signs or symptoms suggestive of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Persistent liver function test abnormalities and/or depression of serum albumin may require evaluation, including a liver biopsy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6262, 22652, 'Methotrexate', 'Liver Diseases', 'The use of methotrexate is contraindicated as treatment for psoriasis or rheumatoid arthritis in patients with alcoholism, alcoholic liver disease or other chronic liver diseases.  Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, usually after long-term therapy.  Fibrosis and cirrhosis may not be preceded by symptoms or abnormal liver function tests.  If methotrexate is used, patients should be instructed to immediately report any signs or symptoms suggestive of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Persistent liver function test abnormalities and/or depression of serum albumin may require evaluation, including a liver biopsy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6263, 22653, 'Methotrexate', 'Liver Diseases', 'The use of methotrexate is contraindicated as treatment for psoriasis or rheumatoid arthritis in patients with alcoholism, alcoholic liver disease or other chronic liver diseases.  Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, usually after long-term therapy.  Fibrosis and cirrhosis may not be preceded by symptoms or abnormal liver function tests.  If methotrexate is used, patients should be instructed to immediately report any signs or symptoms suggestive of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Persistent liver function test abnormalities and/or depression of serum albumin may require evaluation, including a liver biopsy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6264, 22654, 'Methotrexate', 'Liver Diseases', 'The use of methotrexate is contraindicated as treatment for psoriasis or rheumatoid arthritis in patients with alcoholism, alcoholic liver disease or other chronic liver diseases.  Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, usually after long-term therapy.  Fibrosis and cirrhosis may not be preceded by symptoms or abnormal liver function tests.  If methotrexate is used, patients should be instructed to immediately report any signs or symptoms suggestive of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Persistent liver function test abnormalities and/or depression of serum albumin may require evaluation, including a liver biopsy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6265, 22655, 'Methotrexate', 'Liver Diseases', 'The use of methotrexate is contraindicated as treatment for psoriasis or rheumatoid arthritis in patients with alcoholism, alcoholic liver disease or other chronic liver diseases.  Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, usually after long-term therapy.  Fibrosis and cirrhosis may not be preceded by symptoms or abnormal liver function tests.  If methotrexate is used, patients should be instructed to immediately report any signs or symptoms suggestive of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Persistent liver function test abnormalities and/or depression of serum albumin may require evaluation, including a liver biopsy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6266, 22657, 'Methotrexate', 'Liver Diseases', 'The use of methotrexate is contraindicated as treatment for psoriasis or rheumatoid arthritis in patients with alcoholism, alcoholic liver disease or other chronic liver diseases.  Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, usually after long-term therapy.  Fibrosis and cirrhosis may not be preceded by symptoms or abnormal liver function tests.  If methotrexate is used, patients should be instructed to immediately report any signs or symptoms suggestive of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Persistent liver function test abnormalities and/or depression of serum albumin may require evaluation, including a liver biopsy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6267, 22786, 'Methotrexate', 'Liver Diseases', 'The use of methotrexate is contraindicated as treatment for psoriasis or rheumatoid arthritis in patients with alcoholism, alcoholic liver disease or other chronic liver diseases.  Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, usually after long-term therapy.  Fibrosis and cirrhosis may not be preceded by symptoms or abnormal liver function tests.  If methotrexate is used, patients should be instructed to immediately report any signs or symptoms suggestive of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Persistent liver function test abnormalities and/or depression of serum albumin may require evaluation, including a liver biopsy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6268, 23055, 'Methotrexate', 'Liver Diseases', 'The use of methotrexate is contraindicated as treatment for psoriasis or rheumatoid arthritis in patients with alcoholism, alcoholic liver disease or other chronic liver diseases.  Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, usually after long-term therapy.  Fibrosis and cirrhosis may not be preceded by symptoms or abnormal liver function tests.  If methotrexate is used, patients should be instructed to immediately report any signs or symptoms suggestive of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Persistent liver function test abnormalities and/or depression of serum albumin may require evaluation, including a liver biopsy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6269, 23056, 'Methotrexate', 'Liver Diseases', 'The use of methotrexate is contraindicated as treatment for psoriasis or rheumatoid arthritis in patients with alcoholism, alcoholic liver disease or other chronic liver diseases.  Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, usually after long-term therapy.  Fibrosis and cirrhosis may not be preceded by symptoms or abnormal liver function tests.  If methotrexate is used, patients should be instructed to immediately report any signs or symptoms suggestive of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Persistent liver function test abnormalities and/or depression of serum albumin may require evaluation, including a liver biopsy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6270, 28776, 'Methotrexate', 'Liver Diseases', 'The use of methotrexate is contraindicated as treatment for psoriasis or rheumatoid arthritis in patients with alcoholism, alcoholic liver disease or other chronic liver diseases.  Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, usually after long-term therapy.  Fibrosis and cirrhosis may not be preceded by symptoms or abnormal liver function tests.  If methotrexate is used, patients should be instructed to immediately report any signs or symptoms suggestive of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Persistent liver function test abnormalities and/or depression of serum albumin may require evaluation, including a liver biopsy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6271, 28778, 'Methotrexate', 'Liver Diseases', 'The use of methotrexate is contraindicated as treatment for psoriasis or rheumatoid arthritis in patients with alcoholism, alcoholic liver disease or other chronic liver diseases.  Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, usually after long-term therapy.  Fibrosis and cirrhosis may not be preceded by symptoms or abnormal liver function tests.  If methotrexate is used, patients should be instructed to immediately report any signs or symptoms suggestive of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Persistent liver function test abnormalities and/or depression of serum albumin may require evaluation, including a liver biopsy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6272, 28779, 'Methotrexate', 'Liver Diseases', 'The use of methotrexate is contraindicated as treatment for psoriasis or rheumatoid arthritis in patients with alcoholism, alcoholic liver disease or other chronic liver diseases.  Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, usually after long-term therapy.  Fibrosis and cirrhosis may not be preceded by symptoms or abnormal liver function tests.  If methotrexate is used, patients should be instructed to immediately report any signs or symptoms suggestive of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Persistent liver function test abnormalities and/or depression of serum albumin may require evaluation, including a liver biopsy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6273, 32982, 'Methotrexate', 'Liver Diseases', 'The use of methotrexate is contraindicated as treatment for psoriasis or rheumatoid arthritis in patients with alcoholism, alcoholic liver disease or other chronic liver diseases.  Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, usually after long-term therapy.  Fibrosis and cirrhosis may not be preceded by symptoms or abnormal liver function tests.  If methotrexate is used, patients should be instructed to immediately report any signs or symptoms suggestive of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Persistent liver function test abnormalities and/or depression of serum albumin may require evaluation, including a liver biopsy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6274, 32983, 'Methotrexate', 'Liver Diseases', 'The use of methotrexate is contraindicated as treatment for psoriasis or rheumatoid arthritis in patients with alcoholism, alcoholic liver disease or other chronic liver diseases.  Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, usually after long-term therapy.  Fibrosis and cirrhosis may not be preceded by symptoms or abnormal liver function tests.  If methotrexate is used, patients should be instructed to immediately report any signs or symptoms suggestive of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Persistent liver function test abnormalities and/or depression of serum albumin may require evaluation, including a liver biopsy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6275, 33198, 'Methotrexate', 'Liver Diseases', 'The use of methotrexate is contraindicated as treatment for psoriasis or rheumatoid arthritis in patients with alcoholism, alcoholic liver disease or other chronic liver diseases.  Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, usually after long-term therapy.  Fibrosis and cirrhosis may not be preceded by symptoms or abnormal liver function tests.  If methotrexate is used, patients should be instructed to immediately report any signs or symptoms suggestive of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Persistent liver function test abnormalities and/or depression of serum albumin may require evaluation, including a liver biopsy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6276, 5019, 'Methotrexate', 'Bone Marrow Failure Disorders', 'Methotrexate can induce myelosuppression causing leukopenia, thrombocytopenia, neutropenia, pancytopenia and anemia.  Therapy with methotrexate is contraindicated as treatment of psoriasis in patients with bone marrow suppression or preexisting blood dyscrasias.  Methotrexate should be discontinued immediately in patients with psoriasis or rheumatoid arthritis if there is a significant fall in blood cell counts.  If need outweighs risk, therapy with methotrexate should be administered cautiously in patients with malignancy and hematopoietic impairment.  Additionally, methotrexate should be used with extreme caution in patients with active infection, and it is usually contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression or infection such as fever, sore throat, or bleeding.  Clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6277, 8089, 'Methotrexate', 'Bone Marrow Failure Disorders', 'Methotrexate can induce myelosuppression causing leukopenia, thrombocytopenia, neutropenia, pancytopenia and anemia.  Therapy with methotrexate is contraindicated as treatment of psoriasis in patients with bone marrow suppression or preexisting blood dyscrasias.  Methotrexate should be discontinued immediately in patients with psoriasis or rheumatoid arthritis if there is a significant fall in blood cell counts.  If need outweighs risk, therapy with methotrexate should be administered cautiously in patients with malignancy and hematopoietic impairment.  Additionally, methotrexate should be used with extreme caution in patients with active infection, and it is usually contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression or infection such as fever, sore throat, or bleeding.  Clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6278, 11930, 'Methotrexate', 'Bone Marrow Failure Disorders', 'Methotrexate can induce myelosuppression causing leukopenia, thrombocytopenia, neutropenia, pancytopenia and anemia.  Therapy with methotrexate is contraindicated as treatment of psoriasis in patients with bone marrow suppression or preexisting blood dyscrasias.  Methotrexate should be discontinued immediately in patients with psoriasis or rheumatoid arthritis if there is a significant fall in blood cell counts.  If need outweighs risk, therapy with methotrexate should be administered cautiously in patients with malignancy and hematopoietic impairment.  Additionally, methotrexate should be used with extreme caution in patients with active infection, and it is usually contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression or infection such as fever, sore throat, or bleeding.  Clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6279, 14338, 'Methotrexate', 'Bone Marrow Failure Disorders', 'Methotrexate can induce myelosuppression causing leukopenia, thrombocytopenia, neutropenia, pancytopenia and anemia.  Therapy with methotrexate is contraindicated as treatment of psoriasis in patients with bone marrow suppression or preexisting blood dyscrasias.  Methotrexate should be discontinued immediately in patients with psoriasis or rheumatoid arthritis if there is a significant fall in blood cell counts.  If need outweighs risk, therapy with methotrexate should be administered cautiously in patients with malignancy and hematopoietic impairment.  Additionally, methotrexate should be used with extreme caution in patients with active infection, and it is usually contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression or infection such as fever, sore throat, or bleeding.  Clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6280, 14594, 'Methotrexate', 'Bone Marrow Failure Disorders', 'Methotrexate can induce myelosuppression causing leukopenia, thrombocytopenia, neutropenia, pancytopenia and anemia.  Therapy with methotrexate is contraindicated as treatment of psoriasis in patients with bone marrow suppression or preexisting blood dyscrasias.  Methotrexate should be discontinued immediately in patients with psoriasis or rheumatoid arthritis if there is a significant fall in blood cell counts.  If need outweighs risk, therapy with methotrexate should be administered cautiously in patients with malignancy and hematopoietic impairment.  Additionally, methotrexate should be used with extreme caution in patients with active infection, and it is usually contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression or infection such as fever, sore throat, or bleeding.  Clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6281, 18291, 'Methotrexate', 'Bone Marrow Failure Disorders', 'Methotrexate can induce myelosuppression causing leukopenia, thrombocytopenia, neutropenia, pancytopenia and anemia.  Therapy with methotrexate is contraindicated as treatment of psoriasis in patients with bone marrow suppression or preexisting blood dyscrasias.  Methotrexate should be discontinued immediately in patients with psoriasis or rheumatoid arthritis if there is a significant fall in blood cell counts.  If need outweighs risk, therapy with methotrexate should be administered cautiously in patients with malignancy and hematopoietic impairment.  Additionally, methotrexate should be used with extreme caution in patients with active infection, and it is usually contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression or infection such as fever, sore throat, or bleeding.  Clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6282, 22641, 'Methotrexate', 'Bone Marrow Failure Disorders', 'Methotrexate can induce myelosuppression causing leukopenia, thrombocytopenia, neutropenia, pancytopenia and anemia.  Therapy with methotrexate is contraindicated as treatment of psoriasis in patients with bone marrow suppression or preexisting blood dyscrasias.  Methotrexate should be discontinued immediately in patients with psoriasis or rheumatoid arthritis if there is a significant fall in blood cell counts.  If need outweighs risk, therapy with methotrexate should be administered cautiously in patients with malignancy and hematopoietic impairment.  Additionally, methotrexate should be used with extreme caution in patients with active infection, and it is usually contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression or infection such as fever, sore throat, or bleeding.  Clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6283, 22644, 'Methotrexate', 'Bone Marrow Failure Disorders', 'Methotrexate can induce myelosuppression causing leukopenia, thrombocytopenia, neutropenia, pancytopenia and anemia.  Therapy with methotrexate is contraindicated as treatment of psoriasis in patients with bone marrow suppression or preexisting blood dyscrasias.  Methotrexate should be discontinued immediately in patients with psoriasis or rheumatoid arthritis if there is a significant fall in blood cell counts.  If need outweighs risk, therapy with methotrexate should be administered cautiously in patients with malignancy and hematopoietic impairment.  Additionally, methotrexate should be used with extreme caution in patients with active infection, and it is usually contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression or infection such as fever, sore throat, or bleeding.  Clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6284, 22645, 'Methotrexate', 'Bone Marrow Failure Disorders', 'Methotrexate can induce myelosuppression causing leukopenia, thrombocytopenia, neutropenia, pancytopenia and anemia.  Therapy with methotrexate is contraindicated as treatment of psoriasis in patients with bone marrow suppression or preexisting blood dyscrasias.  Methotrexate should be discontinued immediately in patients with psoriasis or rheumatoid arthritis if there is a significant fall in blood cell counts.  If need outweighs risk, therapy with methotrexate should be administered cautiously in patients with malignancy and hematopoietic impairment.  Additionally, methotrexate should be used with extreme caution in patients with active infection, and it is usually contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression or infection such as fever, sore throat, or bleeding.  Clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6285, 22647, 'Methotrexate', 'Bone Marrow Failure Disorders', 'Methotrexate can induce myelosuppression causing leukopenia, thrombocytopenia, neutropenia, pancytopenia and anemia.  Therapy with methotrexate is contraindicated as treatment of psoriasis in patients with bone marrow suppression or preexisting blood dyscrasias.  Methotrexate should be discontinued immediately in patients with psoriasis or rheumatoid arthritis if there is a significant fall in blood cell counts.  If need outweighs risk, therapy with methotrexate should be administered cautiously in patients with malignancy and hematopoietic impairment.  Additionally, methotrexate should be used with extreme caution in patients with active infection, and it is usually contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression or infection such as fever, sore throat, or bleeding.  Clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6286, 22648, 'Methotrexate', 'Bone Marrow Failure Disorders', 'Methotrexate can induce myelosuppression causing leukopenia, thrombocytopenia, neutropenia, pancytopenia and anemia.  Therapy with methotrexate is contraindicated as treatment of psoriasis in patients with bone marrow suppression or preexisting blood dyscrasias.  Methotrexate should be discontinued immediately in patients with psoriasis or rheumatoid arthritis if there is a significant fall in blood cell counts.  If need outweighs risk, therapy with methotrexate should be administered cautiously in patients with malignancy and hematopoietic impairment.  Additionally, methotrexate should be used with extreme caution in patients with active infection, and it is usually contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression or infection such as fever, sore throat, or bleeding.  Clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6287, 22649, 'Methotrexate', 'Bone Marrow Failure Disorders', 'Methotrexate can induce myelosuppression causing leukopenia, thrombocytopenia, neutropenia, pancytopenia and anemia.  Therapy with methotrexate is contraindicated as treatment of psoriasis in patients with bone marrow suppression or preexisting blood dyscrasias.  Methotrexate should be discontinued immediately in patients with psoriasis or rheumatoid arthritis if there is a significant fall in blood cell counts.  If need outweighs risk, therapy with methotrexate should be administered cautiously in patients with malignancy and hematopoietic impairment.  Additionally, methotrexate should be used with extreme caution in patients with active infection, and it is usually contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression or infection such as fever, sore throat, or bleeding.  Clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6288, 22650, 'Methotrexate', 'Bone Marrow Failure Disorders', 'Methotrexate can induce myelosuppression causing leukopenia, thrombocytopenia, neutropenia, pancytopenia and anemia.  Therapy with methotrexate is contraindicated as treatment of psoriasis in patients with bone marrow suppression or preexisting blood dyscrasias.  Methotrexate should be discontinued immediately in patients with psoriasis or rheumatoid arthritis if there is a significant fall in blood cell counts.  If need outweighs risk, therapy with methotrexate should be administered cautiously in patients with malignancy and hematopoietic impairment.  Additionally, methotrexate should be used with extreme caution in patients with active infection, and it is usually contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression or infection such as fever, sore throat, or bleeding.  Clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6289, 22651, 'Methotrexate', 'Bone Marrow Failure Disorders', 'Methotrexate can induce myelosuppression causing leukopenia, thrombocytopenia, neutropenia, pancytopenia and anemia.  Therapy with methotrexate is contraindicated as treatment of psoriasis in patients with bone marrow suppression or preexisting blood dyscrasias.  Methotrexate should be discontinued immediately in patients with psoriasis or rheumatoid arthritis if there is a significant fall in blood cell counts.  If need outweighs risk, therapy with methotrexate should be administered cautiously in patients with malignancy and hematopoietic impairment.  Additionally, methotrexate should be used with extreme caution in patients with active infection, and it is usually contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression or infection such as fever, sore throat, or bleeding.  Clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6290, 22652, 'Methotrexate', 'Bone Marrow Failure Disorders', 'Methotrexate can induce myelosuppression causing leukopenia, thrombocytopenia, neutropenia, pancytopenia and anemia.  Therapy with methotrexate is contraindicated as treatment of psoriasis in patients with bone marrow suppression or preexisting blood dyscrasias.  Methotrexate should be discontinued immediately in patients with psoriasis or rheumatoid arthritis if there is a significant fall in blood cell counts.  If need outweighs risk, therapy with methotrexate should be administered cautiously in patients with malignancy and hematopoietic impairment.  Additionally, methotrexate should be used with extreme caution in patients with active infection, and it is usually contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression or infection such as fever, sore throat, or bleeding.  Clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6291, 22653, 'Methotrexate', 'Bone Marrow Failure Disorders', 'Methotrexate can induce myelosuppression causing leukopenia, thrombocytopenia, neutropenia, pancytopenia and anemia.  Therapy with methotrexate is contraindicated as treatment of psoriasis in patients with bone marrow suppression or preexisting blood dyscrasias.  Methotrexate should be discontinued immediately in patients with psoriasis or rheumatoid arthritis if there is a significant fall in blood cell counts.  If need outweighs risk, therapy with methotrexate should be administered cautiously in patients with malignancy and hematopoietic impairment.  Additionally, methotrexate should be used with extreme caution in patients with active infection, and it is usually contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression or infection such as fever, sore throat, or bleeding.  Clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6292, 22654, 'Methotrexate', 'Bone Marrow Failure Disorders', 'Methotrexate can induce myelosuppression causing leukopenia, thrombocytopenia, neutropenia, pancytopenia and anemia.  Therapy with methotrexate is contraindicated as treatment of psoriasis in patients with bone marrow suppression or preexisting blood dyscrasias.  Methotrexate should be discontinued immediately in patients with psoriasis or rheumatoid arthritis if there is a significant fall in blood cell counts.  If need outweighs risk, therapy with methotrexate should be administered cautiously in patients with malignancy and hematopoietic impairment.  Additionally, methotrexate should be used with extreme caution in patients with active infection, and it is usually contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression or infection such as fever, sore throat, or bleeding.  Clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6293, 22655, 'Methotrexate', 'Bone Marrow Failure Disorders', 'Methotrexate can induce myelosuppression causing leukopenia, thrombocytopenia, neutropenia, pancytopenia and anemia.  Therapy with methotrexate is contraindicated as treatment of psoriasis in patients with bone marrow suppression or preexisting blood dyscrasias.  Methotrexate should be discontinued immediately in patients with psoriasis or rheumatoid arthritis if there is a significant fall in blood cell counts.  If need outweighs risk, therapy with methotrexate should be administered cautiously in patients with malignancy and hematopoietic impairment.  Additionally, methotrexate should be used with extreme caution in patients with active infection, and it is usually contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression or infection such as fever, sore throat, or bleeding.  Clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6294, 22657, 'Methotrexate', 'Bone Marrow Failure Disorders', 'Methotrexate can induce myelosuppression causing leukopenia, thrombocytopenia, neutropenia, pancytopenia and anemia.  Therapy with methotrexate is contraindicated as treatment of psoriasis in patients with bone marrow suppression or preexisting blood dyscrasias.  Methotrexate should be discontinued immediately in patients with psoriasis or rheumatoid arthritis if there is a significant fall in blood cell counts.  If need outweighs risk, therapy with methotrexate should be administered cautiously in patients with malignancy and hematopoietic impairment.  Additionally, methotrexate should be used with extreme caution in patients with active infection, and it is usually contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression or infection such as fever, sore throat, or bleeding.  Clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6295, 22786, 'Methotrexate', 'Bone Marrow Failure Disorders', 'Methotrexate can induce myelosuppression causing leukopenia, thrombocytopenia, neutropenia, pancytopenia and anemia.  Therapy with methotrexate is contraindicated as treatment of psoriasis in patients with bone marrow suppression or preexisting blood dyscrasias.  Methotrexate should be discontinued immediately in patients with psoriasis or rheumatoid arthritis if there is a significant fall in blood cell counts.  If need outweighs risk, therapy with methotrexate should be administered cautiously in patients with malignancy and hematopoietic impairment.  Additionally, methotrexate should be used with extreme caution in patients with active infection, and it is usually contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression or infection such as fever, sore throat, or bleeding.  Clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6296, 23055, 'Methotrexate', 'Bone Marrow Failure Disorders', 'Methotrexate can induce myelosuppression causing leukopenia, thrombocytopenia, neutropenia, pancytopenia and anemia.  Therapy with methotrexate is contraindicated as treatment of psoriasis in patients with bone marrow suppression or preexisting blood dyscrasias.  Methotrexate should be discontinued immediately in patients with psoriasis or rheumatoid arthritis if there is a significant fall in blood cell counts.  If need outweighs risk, therapy with methotrexate should be administered cautiously in patients with malignancy and hematopoietic impairment.  Additionally, methotrexate should be used with extreme caution in patients with active infection, and it is usually contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression or infection such as fever, sore throat, or bleeding.  Clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6297, 23056, 'Methotrexate', 'Bone Marrow Failure Disorders', 'Methotrexate can induce myelosuppression causing leukopenia, thrombocytopenia, neutropenia, pancytopenia and anemia.  Therapy with methotrexate is contraindicated as treatment of psoriasis in patients with bone marrow suppression or preexisting blood dyscrasias.  Methotrexate should be discontinued immediately in patients with psoriasis or rheumatoid arthritis if there is a significant fall in blood cell counts.  If need outweighs risk, therapy with methotrexate should be administered cautiously in patients with malignancy and hematopoietic impairment.  Additionally, methotrexate should be used with extreme caution in patients with active infection, and it is usually contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression or infection such as fever, sore throat, or bleeding.  Clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6298, 28776, 'Methotrexate', 'Bone Marrow Failure Disorders', 'Methotrexate can induce myelosuppression causing leukopenia, thrombocytopenia, neutropenia, pancytopenia and anemia.  Therapy with methotrexate is contraindicated as treatment of psoriasis in patients with bone marrow suppression or preexisting blood dyscrasias.  Methotrexate should be discontinued immediately in patients with psoriasis or rheumatoid arthritis if there is a significant fall in blood cell counts.  If need outweighs risk, therapy with methotrexate should be administered cautiously in patients with malignancy and hematopoietic impairment.  Additionally, methotrexate should be used with extreme caution in patients with active infection, and it is usually contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression or infection such as fever, sore throat, or bleeding.  Clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6299, 28778, 'Methotrexate', 'Bone Marrow Failure Disorders', 'Methotrexate can induce myelosuppression causing leukopenia, thrombocytopenia, neutropenia, pancytopenia and anemia.  Therapy with methotrexate is contraindicated as treatment of psoriasis in patients with bone marrow suppression or preexisting blood dyscrasias.  Methotrexate should be discontinued immediately in patients with psoriasis or rheumatoid arthritis if there is a significant fall in blood cell counts.  If need outweighs risk, therapy with methotrexate should be administered cautiously in patients with malignancy and hematopoietic impairment.  Additionally, methotrexate should be used with extreme caution in patients with active infection, and it is usually contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression or infection such as fever, sore throat, or bleeding.  Clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6300, 28779, 'Methotrexate', 'Bone Marrow Failure Disorders', 'Methotrexate can induce myelosuppression causing leukopenia, thrombocytopenia, neutropenia, pancytopenia and anemia.  Therapy with methotrexate is contraindicated as treatment of psoriasis in patients with bone marrow suppression or preexisting blood dyscrasias.  Methotrexate should be discontinued immediately in patients with psoriasis or rheumatoid arthritis if there is a significant fall in blood cell counts.  If need outweighs risk, therapy with methotrexate should be administered cautiously in patients with malignancy and hematopoietic impairment.  Additionally, methotrexate should be used with extreme caution in patients with active infection, and it is usually contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression or infection such as fever, sore throat, or bleeding.  Clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
